Skip to main content
Top
Published in: Cancer Causes & Control 4/2017

01-04-2017 | Original paper

Unstaged cancer: Long-term decline in incidence by site and by demographic and socioeconomic characteristics

Authors: Kimberly Herget, Antoinette Stroup, Ken Smith, Ming Wen, Carol Sweeney

Published in: Cancer Causes & Control | Issue 4/2017

Login to get access

Abstract

Purpose

The study of trends in stage at diagnosis contributes to understand disease burden and the effects of cancer control activities. However, a proportion of cancers reported to registries have insufficient information to assign stage. The limited research addressing unstaged cancers has noted racial and socioeconomic disparities. Long-term incidence trends for unstaged cancers have not been described. We examined long-term trends in diagnosis of unstaged cancers in the U.S. Surveillance, Epidemiology and End Results (SEER) reporting areas.

Methods

Incidence of unstaged invasive cancers for primary sites that have a staging scheme was analyzed for the years 1992–2011. JoinPoint regression was used to describe incidence rate trends of unstaged cancers, with analysis stratified by cancer site and by socioeconomic and demographic variables.

Results

From 1992 to 1996, 8.6% of invasive cancers were unstaged. A steep decline in the incidence of unstaged cancers, represented by an annual percent change (APC) of −9.16%, was observed from 1997 to 2001, followed by a modest decline. By the end of the study period, 2007–2011, unstaged cancers represented 4.9% of invasive cancers. Unstaged cancers are disproportionately more common for older individuals and those in lower socioeconomic communities.

Conclusion

The incidence of unstaged cancers decreased markedly over the period studied. Change in ability to assign stage was seen, possibly related to increased use of advanced imaging like PET scans, and should be considered when evaluating changes in cancer stage distributions over time.
Literature
1.
go back to reference Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, Anderson RN, Ma J, Ly KN, Cronin KA, Penberthy L, Kohler BA (2016) Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer 122(9):1312–1337. doi:10.1002/cncr.29936 CrossRefPubMed Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, Anderson RN, Ma J, Ly KN, Cronin KA, Penberthy L, Kohler BA (2016) Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer 122(9):1312–1337. doi:10.​1002/​cncr.​29936 CrossRefPubMed
13.
go back to reference Hsieh MC, Yu Q, Wu XC, Wohler B, Fan Y, Qiao B, Jemal A, Ajani UA (2012) Evaluating factors associated with unknown SEER Summary Stage 2000 derived from collaborative stage at central registry level. J Registry Manag 39(3):101–106PubMed Hsieh MC, Yu Q, Wu XC, Wohler B, Fan Y, Qiao B, Jemal A, Ajani UA (2012) Evaluating factors associated with unknown SEER Summary Stage 2000 derived from collaborative stage at central registry level. J Registry Manag 39(3):101–106PubMed
16.
go back to reference Wu XC, Yu Q, Andrews PA, Ranganath P, Qiao B, Ajani U, Wohler B, Zhang Z (2010) Comparisons of directly coded SEER Summary Stage 2000 and Collaborative Staging Derived SEER Summary Stage 2000. J Registry Manag 37(4):137–140PubMed Wu XC, Yu Q, Andrews PA, Ranganath P, Qiao B, Ajani U, Wohler B, Zhang Z (2010) Comparisons of directly coded SEER Summary Stage 2000 and Collaborative Staging Derived SEER Summary Stage 2000. J Registry Manag 37(4):137–140PubMed
19.
go back to reference Rural–Urban Continuum Code (2003). United States Department of Agriculture, Economic Research Service Rural–Urban Continuum Code (2003). United States Department of Agriculture, Economic Research Service
20.
go back to reference Yost K, Perkins C, Cohen R, Morris C, Wright W (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12(8):703–711CrossRefPubMed Yost K, Perkins C, Cohen R, Morris C, Wright W (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12(8):703–711CrossRefPubMed
21.
go back to reference Joinpoint Regression Program, Version 3.5.2 (2011). Statistical Research and Applications Branch, National Cancer Institute Joinpoint Regression Program, Version 3.5.2 (2011). Statistical Research and Applications Branch, National Cancer Institute
22.
go back to reference Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19(3):335–351CrossRefPubMed Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19(3):335–351CrossRefPubMed
23.
go back to reference Ostenfeld EB, Froslev T, Friis S, Gandrup P, Madsen MR, Sogaard M (2012) Completeness of colon and rectal cancer staging in the Danish Cancer Registry, 2004–2009. Clin Epidemiol 4(Suppl 2):33–38CrossRefPubMedPubMedCentral Ostenfeld EB, Froslev T, Friis S, Gandrup P, Madsen MR, Sogaard M (2012) Completeness of colon and rectal cancer staging in the Danish Cancer Registry, 2004–2009. Clin Epidemiol 4(Suppl 2):33–38CrossRefPubMedPubMedCentral
26.
go back to reference Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, Detterbeck F, American College of Chest P (2007) Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 132 (Suppl 3):178S–201S. doi:10.1378/chest.07-1360 CrossRefPubMed Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, Detterbeck F, American College of Chest P (2007) Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 132 (Suppl 3):178S–201S. doi:10.​1378/​chest.​07-1360 CrossRefPubMed
27.
go back to reference Avril N, Schelling M, Dose J, Weber WA, Schwaiger M (1999) Utility of PET in Breast Cancer. Clin Positron Imaging 2(5):261–271CrossRefPubMed Avril N, Schelling M, Dose J, Weber WA, Schwaiger M (1999) Utility of PET in Breast Cancer. Clin Positron Imaging 2(5):261–271CrossRefPubMed
28.
go back to reference Smith IC, Ogston KN, Whitford P, Smith FW, Sharp P, Norton M, Miller ID, Ah-See AK, Heys SD, Jibril JA, Eremin O (1998) Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-d-glucose. Ann Surg 228(2):220–227CrossRefPubMedPubMedCentral Smith IC, Ogston KN, Whitford P, Smith FW, Sharp P, Norton M, Miller ID, Ah-See AK, Heys SD, Jibril JA, Eremin O (1998) Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-d-glucose. Ann Surg 228(2):220–227CrossRefPubMedPubMedCentral
29.
go back to reference Utech CI, Young CS, Winter PF (1996) Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 23(12):1588–1593CrossRefPubMed Utech CI, Young CS, Winter PF (1996) Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 23(12):1588–1593CrossRefPubMed
30.
go back to reference Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, Coleman RE (2008) Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 49(12):1928–1935. doi:10.2967/jnumed.108.056713 CrossRefPubMed Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, Coleman RE (2008) Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 49(12):1928–1935. doi:10.​2967/​jnumed.​108.​056713 CrossRefPubMed
33.
go back to reference Adler SR, Fosket JR, Kagawa-Singer M, McGraw SA, Wong-Kim E, Gold E, Sternfeld B (2000) Conceptualizing menopause and midlife: Chinese American and Chinese women in the U.S. Maturitas 35(1):11–23CrossRefPubMed Adler SR, Fosket JR, Kagawa-Singer M, McGraw SA, Wong-Kim E, Gold E, Sternfeld B (2000) Conceptualizing menopause and midlife: Chinese American and Chinese women in the U.S. Maturitas 35(1):11–23CrossRefPubMed
35.
go back to reference Jorgensen TL, Teiblum S, Paludan M, Poulsen LO, Jorgensen AY, Bruun KH, Hallas J, Herrstedt J (2012) Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. Gynecol Oncol 127(2):367–374. doi:10.1016/j.ygyno.2012.07.001 CrossRefPubMed Jorgensen TL, Teiblum S, Paludan M, Poulsen LO, Jorgensen AY, Bruun KH, Hallas J, Herrstedt J (2012) Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. Gynecol Oncol 127(2):367–374. doi:10.​1016/​j.​ygyno.​2012.​07.​001 CrossRefPubMed
36.
go back to reference Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M (2003) Trends in breast cancer by race and ethnicity. CA 53(6):342–355PubMed Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M (2003) Trends in breast cancer by race and ethnicity. CA 53(6):342–355PubMed
37.
go back to reference Shi L, Lebrun LA, Zhu J, Tsai J (2011) Cancer screening among racial/ethnic and insurance groups in the United States: a comparison of disparities in 2000 and 2008. J Health Care Poor Underserved 22(3):945–961. doi:10.1353/hpu.2011.0079 CrossRefPubMed Shi L, Lebrun LA, Zhu J, Tsai J (2011) Cancer screening among racial/ethnic and insurance groups in the United States: a comparison of disparities in 2000 and 2008. J Health Care Poor Underserved 22(3):945–961. doi:10.​1353/​hpu.​2011.​0079 CrossRefPubMed
Metadata
Title
Unstaged cancer: Long-term decline in incidence by site and by demographic and socioeconomic characteristics
Authors
Kimberly Herget
Antoinette Stroup
Ken Smith
Ming Wen
Carol Sweeney
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 4/2017
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0874-2

Other articles of this Issue 4/2017

Cancer Causes & Control 4/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine